Published on
December 10, 2017
- 23:05 GMT
Karyopharm Presents Positive Phase 1/2 Eltanexor Data at the American Society of Hematology 2017 Annual Meeting
− Preliminary Data Show that Eltanexor is Well Tolerated and Demonstrates Promising Activity in Multiple Myeloma – − Expanding Program to Include Colorectal Cancer, Castration-resistant Prostate Cancer, and Myelodysplastic Syndrome – NEWTON, Mass., Dec. 10 …
Distribution channels:
Healthcare & Pharmaceuticals Industry
...
